secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-07-03T23:59:59+00:00
Accession:  0001551152-25-000034
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie expects Q2 2025 acquired IPR&D expense of $823M, lowers adjusted EPS guide
--------------------------------------------------------------------------------

- Acquired IPR&D and milestones expense of $823M pre-tax in Q2 2025 reduces GAAP and adjusted EPS by $0.42.
- Full-year 2025 adjusted diluted EPS guidance range lowered to $11.67-$11.87 from $12.09-$12.29.
- Q2 2025 adjusted diluted EPS guidance range now $2.84-$2.88 versus prior $3.26-$3.30.
- Guidance excludes any acquired IPR&D expense beyond Q2 2025 due to forecasting uncertainty.
- Q2 2025 results are preliminary and subject to financial statement closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000034/0001551152-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000034/abbv-20250703.htm
  HTML page:      https://secwatch.observer/filing/0001551152-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer